Welcome to our dedicated page for PHAXIAM Therapeutics S.A. news (Ticker: PHXM), a resource for investors and traders seeking the latest updates and insights on PHAXIAM Therapeutics S.A. stock.
PHAXIAM Therapeutics S.A. (PHXM), founded in 2004, is a pioneering biopharmaceutical company dedicated to developing innovative therapies that address unmet medical needs, with a significant focus on cancer and orphan diseases. The company leverages its proprietary technology, which is centered on the encapsulation of therapeutic molecules into red blood cells. This encapsulation method presents multiple benefits over free-form compounds, such as minimizing the risk of allergic reactions and allowing the therapeutic substance to remain active in the body for an extended period.
PHAXIAM's flagship product targets relapsed and refractory acute lymphoblastic leukemia by depriving tumors of necessary nutrients. Having completed Phase III development, this product promises a groundbreaking therapeutic solution for patients with this challenging condition. The company's state-of-the-art production facility, located in Lyon, holds “pharmaceutical establishment” status, underscoring its commitment to high-quality manufacturing standards.
PHAXIAM has strategically partnered with Orphan Europe-Recordati (for distribution in Europe) and Teva (for distribution in Israel), enhancing its global reach and ensuring that its innovative therapies are accessible to a broader patient population. Recent developments include various investigator-initiated studies funded by hospital clinical research programs, reflecting the collaborative efforts to advance medical research and patient care.
The company recently reported its FY 2023 financial results and announced the effectiveness of the voluntary delisting of its American Depositary Shares from the NASDAQ Stock Market. PHAXIAM continues to engage with its stakeholders, providing regular updates through webinars and financial disclosures. For more detailed information, stakeholders are encouraged to visit the PHAXIAM website.
PHAXIAM Therapeutics (Euronext: PHXM) announced the results of its Combined General Meeting held on June 28, 2024. Shareholders approved all recommended resolutions, including the annual financial statements for the year ending December 31, 2023, allocation of the year's results, and the remuneration policy for executives. Key approvals included the stock option plan, the appointment of Valérie Faillat as Director, and the delegation of powers to issue shares or convertible securities. Additionally, the Board received authorization to grant free shares, share options, and share warrants to company officers and employees. Full documentation and detailed results are available on the company's website.
PHAXIAM Therapeutics (Euronext: PHXM), a company focused on developing treatments for severe and resistant bacterial infections, has released preparatory documents for its Combined General Meeting scheduled for 28 June 2024. The meeting will take place at 9:30 a.m. at the company's registered office in Lyon, France. Shareholders can attend in person, vote remotely via post or the Votaccess platform, or assign a proxy to vote on their behalf. The documents, including the agenda and draft resolutions, are available on PHAXIAM's website. Shareholders are encouraged to check the site regularly for updates.
As of May 31, 2024, PHXM reported no change in the total number of shares composing its share capital, remaining at 6,075,105 shares.
The total gross voting rights are 6,226,989, while the net voting rights stand at 6,226,740. These figures indicate slight fluctuations over the past five months, with minor variations in both gross and net voting rights.
PHXM's shares are listed on the Euronext Paris market under the ISIN Code FR001400K4B1.
PHAXIAM Therapeutics, a biopharmaceutical firm specializing in phage therapy for bacterial infections, has released its Q1 2024 business and financial update. The company is advancing its Staphylococcus aureus programs, including a global Phase 2 study for Prosthetic Joint Infections (PJI) and a Phase 1 study for Endocarditis Infections (EI). Upcoming milestones include preliminary PK data (3Q 2024) and the launch of the global Phase 2 PJI study (1Q 2025). As of March 31, 2024, PHAXIAM held €5.8 million in cash, sufficient to fund operations until August 2024. Efforts are underway to secure additional financing.
PHXM releases monthly information on the total number of voting rights and shares composing the share capital for April 30, 2024. The data shows consistency in the number of shares and voting rights over the past few months, with 6,075,105 shares and 6,226,932 gross and net voting rights, respectively.
FAQ
What is the market cap of PHAXIAM Therapeutics S.A. (PHXM)?
What does PHAXIAM Therapeutics specialize in?
What is the core technology of PHAXIAM Therapeutics?
What is PHAXIAM's lead product?
Where is PHAXIAM's production facility located?
Who are PHAXIAM's distribution partners?
What recent financial updates has PHAXIAM provided?
How can I stay informed about PHAXIAM's latest developments?
What recent studies has PHAXIAM been involved in?
What are the benefits of PHAXIAM’s encapsulation technology?
Where can I find more information about PHAXIAM Therapeutics?
